| scholarly article | Q13442814 |
| P50 | author | Hazel M. Inskip | Q46484636 |
| P2093 | author name string | A J Hall | |
| H C Whittle | |||
| J Chotard | |||
| M Fortuin | |||
| M Mendy | |||
| M O George | |||
| A D Jack | |||
| N P Maine | |||
| P433 | issue | 8853 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | The Gambia | Q1005 |
| hepatitis B | Q6853 | ||
| Hepatitis B vaccine | Q117749 | ||
| P1104 | number of pages | 3 | |
| P304 | page(s) | 1129-1131 | |
| P577 | publication date | 1993-05-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation | |
| P478 | volume | 341 |
| Q74252431 | Analysis of the relationship between immunogenicity and immunity for viral subunit vaccines |
| Q73235869 | Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine |
| Q74617527 | Assessment of long-term efficacy of hepatitis B vaccine |
| Q40491898 | Clinical aspects of hepatitis B virus infection |
| Q44450238 | Do bedbugs transmit hepatitis B? |
| Q38231641 | Effectiveness of individual-focused interventions to prevent chronic disease |
| Q35084497 | Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program |
| Q41349327 | Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus |
| Q40534051 | Epigenesis: the missing beat in biotechnology? |
| Q53274321 | Evaluation of research on interventions aligned to WHO 'Best Buys' for NCDs in low-income and lower-middle-income countries: a systematic review from 1990 to 2015. |
| Q37233997 | Gastroenterology in developing countries: issues and advances |
| Q36860696 | HBV Perinatal Transmission |
| Q84500535 | Hepatitis B (prevention) |
| Q24241852 | Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status |
| Q34737105 | Hepatitis B immunization and hepatocellular carcinoma: The Gambia Hepatitis Intervention Study |
| Q46263138 | Hepatitis B infection and aflatoxin biomarker levels in Gambian children |
| Q78171051 | Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age |
| Q43152234 | Hepatitis B vaccination: protection for how long and against what? |
| Q36075755 | Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. |
| Q33325499 | Host genetic factors and vaccine-induced immunity to hepatitis B virus infection |
| Q33753902 | Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks |
| Q33673985 | Immunisation strategies for viral diseases in developing countries |
| Q35874803 | Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. |
| Q34472882 | Infantile hepatitis B in immunized children: risk for fulminant hepatitis and long-term outcomes. |
| Q33750371 | Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach |
| Q34412410 | Is Universal HBV Vaccination of Healthcare Workers a Relevant Strategy in Developing Endemic Countries? The Case of a University Hospital in Niger |
| Q28083160 | Is mother-to-infant transmission the most important factor for persistent HBV infection? |
| Q39590904 | Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages |
| Q45445842 | Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants |
| Q72024327 | Measles, polio and tetanus toxoid antibody levels in Gambian children aged 3 to 4 years following routine vaccination |
| Q77466560 | Molecular basis of vaccination |
| Q34637622 | Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose |
| Q28742762 | Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection |
| Q43216165 | Prevention of hepatocellular cancer: one of the most cost-effective ways to reduce adult mortality? |
| Q33892906 | Primary prevention of hepatocellular carcinoma in developing countries. |
| Q72152756 | Protective efficacy of hepatitis B vaccination |
| Q57993298 | Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic |
| Q38937023 | Salivary sampling for hepatitis B surface antigen carriage: a sensitive technique suitable for epidemiological studies. |
| Q39513923 | Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme |
| Q47108304 | Strategies for prevention of gastrointestinal cancers in developing countries: a systematic review |
| Q52041901 | Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated? |
| Q92665888 | The changing epidemiology of hepatitis B and C infections in Nanoro, rural Burkina Faso: a random sampling survey |
| Q73822543 | The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu |
| Q47158580 | The status of hepatitis B control in the African region |
| Q33588921 | Update on diagnosis, management, and prevention of hepatitis B virus infection |
Search more.